Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments
- 2 May 2017
- journal article
- review article
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 15 (3) , 142-152
Abstract
Purpose of Review Hereditary multiple exostoses (HME) is a complex musculoskeletal pediatric disorder characterized by osteochondromas that form next to the growth plates of many skeletal elements, including long bones, ribs, and vertebrae. Due to its intricacies and unresolved issues, HME continues to pose major challenges to both clinicians and biomedical researchers. The purpose of this review is to describe and analyze recent advances in this field and point to possible targets and strategies for future biologically based therapeutic intervention. Recent Findings Most HME cases are linked to loss-of-function mutations in EXT1 or EXT2 that encode glycosyltransferases responsible for heparan sulfate (HS) synthesis, leading to HS deficiency. Recent genomic inquiries have extended those findings but have yet to provide a definitive genotype-phenotype correlation. Clinical studies emphasize that in addition to the well-known skeletal problems caused by osteochondromas, HME patients can experience, and suffer from, other symptoms and health complications such as chronic pain and nerve impingement. Laboratory work has produced novel insights into alterations in cellular and molecular mechanisms instigated by HS deficiency and subtending onset and growth of osteochondroma and how such changes could be targeted toward therapeutic ends. Summary HME is a rare and orphan disease and, as such, is being studied only by a handful of clinical and basic investigators. Despite this limitation, significant advances have been made in the last few years, and the future bodes well for deciphering more thoroughly its pathogenesis and, in turn, identifying the most effective treatment for osteochondroma prevention.Keywords
This publication has 90 references indexed in Scilit:
- Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromasScientific Reports, 2013
- Autism-like socio-communicative deficits and stereotypies in mice lacking heparan sulfateProceedings of the National Academy of Sciences, 2012
- Glycobiology and the Growth PlateJournal of Pediatric Orthopaedics, 2011
- Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bonesBone, 2011
- A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostosesProceedings of the National Academy of Sciences, 2010
- Conditional Ablation of the Heparan Sulfate-synthesizing Enzyme Ext1 Leads to Dysregulation of Bone Morphogenic Protein Signaling and Severe Skeletal DefectsJournal of Biological Chemistry, 2010
- A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytesProceedings of the National Academy of Sciences, 2010
- Surfen, a small molecule antagonist of heparan sulfateProceedings of the National Academy of Sciences, 2008
- Heparan sulphate proteoglycans fine-tune mammalian physiologyNature, 2007
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971